We have detected that you are using an Ad Blocker.
PracticeUpdate is free to end users but we rely on advertising to fund our site. Please consider supporting PracticeUpdate by whitelisting us in your ad blocker.
We have sent a message to the email address you have provided, . If this email is not correct, please update your settings with your correct address.
The email address you provided during registration, , does not appear to be valid. Please update your settings with a valid address before to continue using PracticeUpdate.
Please provide your AHPRA Number to ensure that you are given the correct level of access to our site.
Eddy Yang

Eddy Shih-Hsin Yang MD, PhD

Deputy Director and Associate Director for Precision Oncology, UAB Hugh Kaul Precision Medicine Institute, Professor and Vice Chair for Translational Sciences, Department of Radiation Oncology, O’Neal Comprehensive Cancer Center at UAB, Birmingham, AL

Dr. Eddy Yang is the Deputy Director and Associate Director for Precision Oncology at the UAB Hugh Kaul Precision Medicine Institute, co-Leader of the Experimental Therapeutics Program at the O’Neal Comprehensive Cancer Center, and Professor and Vice Chair for Translational Sciences in the Department of Radiation Oncology at UAB.  He is a translational physician-scientist oncologist with particular interest in investigating novel strategies to enhance the therapeutic ratio through rational combinations of targeted therapies.  His research focuses on genitourinary, breast, and head and neck cancers, which have translated in multiple investigator-initiated clinical trials. His work has been supported by various funding sources, and he also has an excellent track record of productivity, including over 100 total publications and clinical translation of laboratory findings into investigator initiated clinical trials. Dr. Yang is also dedicated to training the next generation of physicians and physician-scientists and serves as a mentor on several NIH T32 training grants.

Disclosures

Disclosures:  Advisory Board:  Strata Oncology, Astrazeneca, Clovis, Bayer; Research Funding: Eli Lilly, Puma